Skip to main content

Table 2 Course of disease severity, physiological, and laboratory indices

From: The effect of continuous versus intermittent renal replacement therapy on the outcome of critically ill patients with acute renal failure (CONVINT): a prospective randomized controlled trial

 

Range, units

Group

Day 1

Day 3

Day 5

Day 7

Day 10

Day 15

Day 21

P value

          

Day 1 (day 10)

SOFA score

-

IHD

13.3

13.0

11.5

10.1

7.6

8.3

5.8

n.s. (n.s.)

   

±3.7

±5.1

±4.6

±5.2

±5.0

±4.3

±0.8

 
  

CVVH

13.0

12.2

10.6

9.5

8.2

8.4

4.7

 
   

±4.0

±3.9

±4.2

±5.2

±5.1

±4.4

±7.2

 

TISS-28 score

-

IHD

45.3

42.0

41.2

37.8

29.9

35.8

37.6

n.s. (n.s.)

   

±9.5

±9.1

±9.7

±8.0

±9.0

±6.1

±5.5

 
  

CVVH

46.8

43.3

39.9

37.3

33.8

40.4

25.3

 
   

±10.2

±8.3

±9.1

±12.3

±10.8

±7.9

±17.2

 

Serum creatinine

<1.20 mg/dl

IHD

3.68

3.29

3.17

2.82

2.32

2.54

2.70

n.s. (n.s.)

   

±1.86

±2.59

±1.61

±1.51

±1.40

±1.40

±1.54

 
  

CVVH

3.74

2.18

2.31

2.08

1.93

1.85

1.86

 
   

±1.88

±1.19

±1.36

±1.40

±1.34

±1.42

±1.52

 

Serum urea

14-46 mg/dl

IHD

164.8

121.5

125.4

124.9

105.9

120.4

117.6

n.s. (n.s.)

   

±83.4

±55.8

±50.0

±48.9

±53.9

±48.9

±60.4

 
  

CVVH

155.7

93.4

105.1

107.5

94.4

100.9

94.4

 
   

±70.0

±44.3

±53.2

±48.9

±48.3

±53.3

±65.7

 

Urinary output (24 hours)

>500 ml

IHD

922

944

914

1,331

1,714

1,376

3,570

n.s. (n.s.)

   

±1,299

±1,464

±1,415

±1,624

±1,338

±1,508

±3,614

 
  

CVVH

649

823

1,402

1,645

1,567

1,591

1,964

 
   

±948

±1,323

±1,785

±1,636

±1,474

±2,093

±757

 

pH

7.35-7.45

IHD

7.35

7.37

7.38

7.37

7.39

7.36

7.39

n.s. (n.s.)

   

±0.1

±0.1

±0.1

±0.1

±0.1

±0.1

±0.1

 
  

CVVH

7.36

7.37

7.40

7.38

7.37

7.39

7.39

 
   

±0.1

±0.1

±0.1

±0.2

±0.1

±0.1

±0.2

 

Heart rate

80-100 bpm

IHD

104.0

93.8

90.9

92.9

86.9

85.5

86.5

n.s. (n.s.)

   

±26.1

±23.3

±20.3

±17.0

±16.4

±19.9

±12.9

 
  

CVVH

105.2

93.6

90.0

87.5

89.7

93.1

96.5

 
   

±21.3

±22.3

±20.4

±19.5

±18.1

±17.2

±15.4

 

Mean arterial pressure

50-80 mm Hg

IHD

73.3

76.5

76.9

82.2

78.1

83.3

70.0

n.s. (n.s.)

   

±16.5

±17.6

±15.9

±16.7

±17.2

±11.9

±15.1

 
  

CVVH

72.0

76.2

76.6

77.7

81.2

75.5

75.3

 
   

±14.1

±13.8

±12.7

±12.4

±14.9

±25.9

±16.5

 

Central venous pressure

8-12 mm Hg

IHD

14.7

12.9

12.2

12.2

11.1

10.7

12.9

n.s. (n.s.)

   

±5.3

±4.9

±3.9

±4.8

±3.9

±3.4

±2.94

 
  

CVVH

14.3

13.6

11.8

10.9

12.3

11.5

11.9

 
   

±5.4

±5.6

±4.2

±3.8

±4.6

±3.6

3.0

 

Temperature

36.5°C-37.5°C

IHD

37.5

37.4

37.2

37.4

37.2

37.7

37.7

n.s. (n.s.)

±1.48

±1.03

±1.3

±0.65

±1.6

±0.67

±0.7

CVVH

37.5

37.1

37.1

37.1

37.2

37.1

37.7

±1.30

±1.16

±0.94

±0.90

±0.91

±1.05

±1.02

C-reactive protein

<0.50 mg/dl

IHD

18.0

15.6

10.5

10.5

8.3

7.14

11.7

n.s. (n.s.)

±10.0

±10.1

±8.3

±7.7

±6.7

±4.95

±8.25

CVVH

18.8

15.9

10.1

9.4

10.0

12.6

10.8

   

±10.3

±9.5

±8.55

±7.2

±7.1

±7.5

±7.6

 
  1. Last column denotes between-group P value (independent-samples t test) at study days 1 and 10. Means ± SD are given.